![](https://d3ilqtpdwi981i.cloudfront.net/fuWrOxuDJRMKs9-DPUQZrIcJNWw=/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/38/46/13/38461313-a07c-4fd9-804e-b606dcdd3dbc/thumbnail_c4648e22-2491-4e29-a252-b3abaf93f07c.jpg)
PURPOSE OF REVIEW: Opioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States' healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy.
RECENT FINDINGS: Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implantable and monthly injectable buprenorphine, and an extended-release injectable naltrexone. Therapies under investigation include various strategies such as heroin vaccines, gene-targeted therapy, and biased agonism at the G protein-coupled receptor (GPCR), but several pharmacologic, clinical, and practical barriers limit these treatments' market viability. This manuscript provides a comprehensive review of the current literature regarding recent innovations in OUD treatment.
Available at: http://works.bepress.com/adam-kaye/108/